Posology The recommended durations of treatment are 5-14 days for cSSTI and 5- 7 days for CAP. Table 1 Dosage in adults with normal renal function, creatinine clearance (CrCL) > 50 mL/min Indications Posology (mg/infusion) Infusion time (minutes)/Frequency Standard dosea Complicated skin and soft tissue infections (cSSTI) Community-acquired pneumonia (CAP) 5 – 60b/every 12 hours High doseb cSSTI confirmed or suspected to be caused by S.
aureus with an MIC = 2 mg/L or 4 mg/L to ceftarolinec 600 mg 120/every 8 hours a For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. b Infusion times of less than 60 minutes and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only.
1. c For treatment of S. aureus for which the ceftaroline MIC is ≤ 1 mg/L, the standard dose is recommended. Table 2 Dosage in paediatric patients with normal renal function, creatinine clearance (CrCL) > 50 mL/min* Indications Age group Posology (mg/infusion) Infusion time (minutes)/Frequency Standard dosea Complicated Adolescents aged from 12 to < 18 years with bodyweight ≥ 33 kg 600 mg 5–60b/every 12 hours Indications Age group Posology (mg/infusion) Infusion time (minutes)/Frequency Adolescents aged from 12 years to < 18 years bodyweight < 33 kg and children ≥ 2 years to < 12 years 12 mg/kg to a maximum of 400 mg 5–60b/every 8 hours Infants ≥ 2 months to < 2 years 8 mg/kg 5–60b/every 8 hours skin and soft tissue infections (cSSTI) Community- acquired pneumonia (CAP) Neonates from birth to < 2 monthsb 6 mg/kg 60/every 8 hours Children and adolescents aged from ≥ 2 years to < 18 years 12 mg/kg to a maximum of 600 mg 120/every 8 hours High doseb cSSTI confirmed or suspected to be caused by S.
aureus with an MIC = 2 mg/L or 4 mg/L to ceftarolinec Infants ≥ 2 months to < 2 years 10 mg/kg 120/every 8 hours a For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable.
b Infusion times of less than 60 minutes, neonatal and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only. 1. c For treatment of S. aureus for which the ceftaroline MIC is ≤ 1 mg/L, the standard dose is recommended.
73 m2) for paediatric patients. 2). 2). The recommended durations of treatment are 5-14 days for cSSTI and 5-7 days for CAP. Table 3 Dosage in adults with impaired renal function, creatinine clearance (CrCL) ≤ 50 mL/min Indications Creatinine clearance (mL/min)a Posology (mg/infusion) Infusion time (minutes)/Frequency > 30 to ≤ 50 400 mg ≥ 15 to ≤ 30 300 mg Standard dose Complicated skin and soft tissue infections(cSSTI) Community- acquired pneumonia (CAP) ESRD, including haemodialysisb 200 mg 5–60c/every 12 hours > 30 to ≤ 50 400 mg ≥ 15 to ≤ 30 300 mg High dosec cSSTI confirmed or suspected to be caused by S.
aureus with an MIC = 2 mg/L or 4 mg/L to ceftarolined ESRD, including haemodialysisb 200 mg 120/every 8 hours a Calculated using the Cockcroft-Gault formula for adults. Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.
b Ceftaroline is haemodialyzable; thus Zinforo should be administered after haemodialysis on haemodialysis days. c Infusion times of less than 60 minutes and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only.
1. d For treatment of S. aureus for which the ceftaroline MIC is ≤ 1 mg/L, the standard dose is recommended. Dose recommendations for neonates, infants and children and adolescents are based on pharmacokinetic (PK) modelling. There is insufficient information to recommend dosage adjustments in adolescents aged from 12 to < 18 years with bodyweight < 33 kg and in children aged from 2 to 12 years with End-stage renal disease (ESRD).
There is insufficient information to recommend dosage adjustments in paediatric patients < 2 years with moderate or severe renal impairment or ESRD. Table 4 Dosage in paediatric patients with impaired renal function, creatinine clearance (CrCL) ≤ 50 mL/min Indications Age group Creatinine clearance (mL/min)a Posology (mg/infusion) Infusion time (minutes)/Fr equency > 30 to ≤ 50 400 mg ≥ 15 to ≤ 30 300 mg Adolescents aged from 12 to < 18 years with bodyweight ≥ 33 kg ESRD, including haemodialysisb 200 mg 5–60c/every 12 hours > 30 to ≤ 50 8 mg/kg to a maximum of 300 mg Standard dose Complicate d skin and soft tissue infections (cSSTI) Community -acquired pneumonia (CAP) Adolescents aged from 12 years to < 18 years bodyweight < 33 kg and children ≥ 2 years to < 12 years ≥ 15 to ≤ 30 6 mg/kg to a maximum of 200 mg 5–60c/every 8 hours > 30 to ≤ 50 10 mg/kg to a maximum of 400mg ≥ 15 to ≤ 30 8 mg/kg to a maximum of 300 mg High dosec cSSTI confirmed or suspected to be caused by S.
73 m2). Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function. b Ceftaroline is haemodialyzable; thus Zinforo should be administered after haemodialysis on haemodialysis days.
c Infusion times of less than 60 minutes and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only. 1. d For treatment of S. aureus for which the ceftaroline MIC is ≤ 1 mg/L, the standard dose is recommended.
Hepatic impairment No […]